Bill Gates, Vaccines and Population Control (Sterilization)

Gates Foundation Invests $10 Million in Vaccines Developer

Liquidia's vaccine (not yet approved) is to be delivered by inhalation -- that means we could be vaccinated without being aware of it – and without permission. Heck, it even could be dispersed from airplanes along with other concoctions which, supposedly, are for our own good. - Realty Zone

March 4, 2011

Bloomberg - The Bill & Melinda Gates Foundation invested $10 million in Liquidia Technologies, a closely held biotechnology company developing vaccines, as part of a $400 million initiative to fund activities to help poorer countries.

Liquidia is developing a seasonal flu vaccine and has an agreement with the PATH Malaria Vaccine Initiative to use its technology to work on new malaria vaccines, the Research Triangle Park, North Carolina-based company said today in an e- mailed statement. The $400 million program provides low-interest loans, loan guarantees and equity investments to help finance organizations that meet the group’s focus areas.

Microsoft Corp. (MSFT) Chairman and co-founder Bill Gates, in his 2010 annual foundation letter, highlighted the need for a malaria vaccine to eradicate the disease, calling it “the highest-risk malaria work we fund.” The foundation has supplied $13.8 billion in global health funding since 1994, according to its website.

“Funding innovation is a key to addressing the unmet health needs of the world’s poorest people,” Doug Holtzman, deputy director for the foundation’s infectious diseases team, said in the statement. “This unique investment partnership will help us advance vaccine development as part of our commitment to help research, develop and deliver vaccines for the world’s poorest countries.”

Liquidia investors also include Canaan Partners, New Enterprise Associates, PPD Inc., Morningside Venture Investments Limited, Pappas Ventures and Firelake Capital, according to the statement.

Liquidia Gets $10M for Vaccine Work

March 3, 2011

The Herald Sun - Morrisville-based Liquidia Technologies received a $10 million equity investment from the Bill & Melinda Gates Foundation, according to a company announcement made Friday.

The investment will be used for the development and commercialization of safe and more effective vaccines and therapeutics, according to a news release, with a focus on malaria and influenza vaccines.

"This unique investment partnership will help us advance vaccine development as part of our commitment to help research, develop and deliver vaccines for the world's poorest countries," Doug Holtzman, deputy director of the foundation's infectious diseases team, said in a release.

In October, Liquidia announced the start of clinical trials for the company's lead seasonal influenza vaccine candidate.

In February, Liquidia announced it would be collaborating with the global health improvement-focused nonprofit PATH through the Malaria Vaccine Initiative to study the use of the company's PRINT particle technology to design malaria vaccines.

Michael Parks, a spokesman for Liquidia, said the company was founded by Joe DeSimone, a chemistry professor at UNC Chapel Hill, based around the development of the company's proprietary PRINT technology.

The technology, which stands for Particle Replication In Non-Wetting Templates according to the company's website liquidia.com, is a manufacturing platform used to create particles that are used as vaccine carriers, Parks said.

"The area of vaccines has obviously been around for some time, the promise of new generation vaccines, if you will, really is going to be somewhat depending on the company's ability to deliver that vaccine in a more safe and effective way," Parks said.

New Malaria Vaccines to Use Liquidia’s Nanotechnology

March 3, 2011

medcitynews.com - The next-generation malaria vaccine could be delivered with nanoparticles made through methods developed by Liquidia Technologies.

The nanotech company, based in North Carolina’s Research Triangle Park, has reached a collaboration agreement with the PATH Malaria Vaccine Initiative to use Liquidia’s patented PRINT method of designing and making nanoparticles. MVI is responsible for malaria vaccine development at PATH, an international nonprofit organization working to improve global health.

MVI was established in 1999 through a $50 million gift from the William H. Gates Foundation. MVI works to accelerate the development of malaria vaccines and to ensure their availability in the developing world. The World Health Organization reports that half of the world’s population is at risk of malaria. It estimates that the 243 million cases in 2008 led to nearly 863,000 deaths. The Bill & Melinda Gates Foundation in 2008 awarded MVI a $168.7 million grant to develop the next-generation malaria vaccine.

Financial terms of Liquidia’s agreement with MVI were not disclosed. Ashley Birkett, MVI’s director of pre- and early clinical research and development, said in a prepared statement that MVI is working to find second-generation vaccine approaches that will be more effective over longer periods of time. Liquidia said that the vaccine candidate will be used to deliver a protein in combination with immune stimulating molecules.

Liquidia was founded by Joseph DeSimone, a chemistry professor who holds dual appointments at the University of North Carolina at Chapel Hill and North Carolina State University. Privately held Liquidia has raised nearly $50 million in equity financing, including a $25 million series C round that closed last April. Its investors include venture capital firms Canaan Partners, New Enterprise Associates, Morningside Venture Investments Limited, Pappas Ventures and Firelake Capital. Wilmington, North Carolina-based clinical research organization PPD (NYSE:PPDI) is also a Liquidia investor.

Liquidia Technologies Has Started Early Clinical Testing of Its First Vaccine Developed Using Nanotechnology

March 3, 2011

News Observer - The Durham company, which has raised $25 million in financing this year, is testing a seasonal flu vaccine aimed at adults over age 65.

Liquidia is also developing cancer treatments and other products based on the nanotechnology research of founder Joseph DeSimone, a chemist at N.C. State University and UNC-Chapel Hill.

The flu vaccine will require years of clinical testing before it can win marketing approval from U.S. regulators. The vaccine is designed to have tiny particles deliver the medicine more safely and effectively.